#Switzerland #Heart Failure #Zug #Berlin Heals #C-MIC

Berlin Heals Secures $10 Million to Revolutionize Heart Failure Treatments

Berlin Heals Holding AG has made headlines by successfully closing a new financing round that garnered over $10 million. This funding, which has come from a mix of both existing shareholders and new investors, is set to enhance the company's groundbreaking cardiac microcurrent technology and expand its clinical research endeavors.

The innovative approach developed by Berlin Heals centers around the Cardiac Microcurrent (C-MIC), an implantable device that has begun showing remarkable clinical results in treating heart failure. The company is keen on leveraging the new capital to continue validating its technology through rigorous studies and presentations at major cardiology conferences. Updated clinical data will be showcased in the upcoming year, alongside new publications that highlight the efficacy of their approach.

In their pursuit to make heart failure treatments less invasive, Berlin Heals is advancing toward improved implantation techniques and device designs. This focus is aimed at broadening the eligibility of patients for therapy while supporting a smoother path for adoption in medical settings. The raised capital will also facilitate the entry into larger clinical trials, laying the groundwork for regulatory submissions, including the FDA IDE application.

Notably, Berlin Heals has already demonstrated significant functional improvements and enhanced quality of life in patients dealing with dilated cardiomyopathy who have been treated with the C-MIC device. The company’s long-term follow-up data has consistently supported the durability and effectiveness of their treatment across early studies.

John Brumfield, the CEO of Berlin Heals Holding AG, emphasized the importance of this financing round, calling it a significant milestone. He expressed gratitude towards Marko Bagaric, Co-Founder and Board Member, for his leadership and vision that propelled the company forward. Brumfield pointed out that having the support of investors who share their vision not only strengthens their foundation but also amplifies their confidence in advancing to less invasive solutions that can have profound impacts on patient care.

Rob ten Hoedt, the Chairman of the Board, noted the pressing necessity for innovative solutions in treating heart failure, as it remains an area with substantial unmet medical needs. He voiced his belief in the potential of Berlin Heals' C-MIC technology to transform the treatment landscape for heart failure patients globally. According to Hoedt, this funding is a game-changer that enables the company to bring its innovative therapies to a much broader segment of patients, significantly enhancing their quality of life.

Founded in 2014, Berlin Heals Holding AG is a Swiss joint-stock company dedicated to developing advanced medical technologies. The C-MIC system delivers a consistent electrical microcurrent to the heart, generating localized electrical fields aimed at improving cardiac function. The early clinical studies highlight the promise of this approach, exhibiting rapid and sustained benefits for patients afflicted with heart failure.

As Berlin Heals embarks on this ambitious journey, they are poised to make a lasting impact in the field of cardiology, driven by their commitment to innovation in medical technology and patient-centered solutions. The future looks bright as they continue their mission to redefine heart failure treatment, ensuring that more patients can access life-changing therapies.